文献速递药物相互作用

Adagrasib 药物相互作用的临床与 PBPK 模型评估

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions.
PubMed 文献 · Clin Pharmacol Ther · 2024-11-25

Adagrasib 是 KRAS G12C 共价抑制剂,同时为 CYP3A4 底物和强抑制剂,多次给药后抑制自身代谢导致时间依赖性 DDI。研究建立并验证 PBPK 模型,预测结果与临床数据在 1.5 倍内,支持 FDA 剂量推荐标签。

要点

  • Adagrasib 600 mg b.i.d. 时,强/中/弱 CYP3A4 抑制剂对稳态暴露影响可忽略。
  • 强和中效 CYP3A4 诱导剂预计分别降低 adagrasib 暴露 68% 和 22%。
  • Adagrasib 600 mg b.i.d. 为强 CYP3A4 抑制剂、中效 CYP2C9/CYP2D6 抑制剂及 P-gp 抑制剂。

核心结论

  • PBPK 模型成功描述 adagrasib 单次和多次给药 PK 及与伊曲康唑、利福平、咪达唑仑、华法林、右美沙芬和地高辛的 DDI 数据。
  • 模型预测支持 adagrasib 与合用药物的剂量推荐,替代临床试验支持标签声明。

研究设计与样本

  • 基于理化、体外和健康志愿者及癌症患者临床 PK 数据建立并验证 PBPK 模型。
  • 模型预测未测试场景,包括批准剂量 600 mg b.i.d. 下的 victim 和 perpetrator DDI 风险。

主要发现

  • 模型预测值与观察到临床数据在 1.5 倍以内。
  • 强、中、弱 CYP3A4 抑制剂对 adagrasib 600 mg b.i.d. 稳态暴露影响可忽略。
  • 强和中效 CYP3A4 诱导剂预计分别降低 adagrasib 暴露 68% 和 22%。
  • Adagrasib 600 mg b.i.d. 预测为强 CYP3A4 抑制剂、中效 CYP2C9 和 CYP2D6 抑制剂及 P-gp 抑制剂。

临床怎么用

  • 临床合用时参考 adagrasib 600 mg b.i.d. 的 PBPK 预测调整剂量。
  • 关注 CYP3A4 诱导剂合用导致 adagrasib 暴露降低。
  • 关注 adagrasib 对 CYP3A4、CYP2C9、CYP2D6 和 P-gp 底物药物的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adagrasib is a potent, highly selective, orally available, small molecule, covalent inhibitor of G12C mutated KRAS. As both a substrate and strong inhibitor of cytochrome P450 (CYP) 3A4, adagrasib inhibits its own CYP3A4-mediated metabolism following multiple dosing, resulting in time-dependent drug-drug interaction (DDI) liabilities. A physiologically-based pharmacokinetic (PBPK) model was developed and verified using a combination of physicochemical, in vitro and clinical pharmacokinetic (PK) data from healthy volunteers and cancer patients. The PBPK model well-described the single and multiple-dose adagrasib PK data as well as DDI data with itraconazole, rifampin, midazolam, warfarin, dextromethorphan, and digoxin, with model predictions within 1.5-fold of the observed clinical data. The PBPK model was used to predict untested scenarios including the clinical victim and perpetrator DDI liabilities at the approved dosing regimen of 600 mg twice daily (b.i.d.) in cancer patients. Strong, moderate, and weak inhibitors of CYP3A4 are predicted to have a negligible effect on the steady-state exposure of adagrasib 600 mg b.i.d. resulting from the significant inactivation of CYP3A4 by adagrasib. Additionally, strong and moderate inducers of CYP3A4 are predicted to decrease adagrasib exposure by 68% and 22%, respectively. As a perpetrator, adagrasib 600 mg b.i.d. is predicted to be a strong inhibitor of CYP3A4, a moderate inhibitor of CYP2C9 and CYP2D6, and an inhibitor of P-glycoprotein (P-gp). These results successfully supported regulatory interactions with the United States Food and Drug Administration regarding dosing recommendations for when adagrasib is used concomitantly with other medications, supporting a range of label claims in lieu of clinical trials.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Cilliers C, Howgate E, Jones HM, et al. Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions. Clin Pharmacol Ther. 2024. PMID: 39587812. doi:10.1002/cpt.3506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。